EPR-Technologies, Inc.

A Cool Way To Save Lives

EPR-Technologies, Inc.

A Cool Way To Save Lives

Closing in 2 days
Gaithersburg, MD
Health Tech
EPR-Technologies is a biomedical company leading advances in emergency medicine to save lives in serious trauma cases and sudden cardiac arrest when needed cardiopulmonary resuscitation (CPR) fails. Serious trauma is one of the leading cause of death in people under 45. The market is huge, and EPR is positioned to capture a very significant share of the rapid market growth following FDA approval of ongoing EPR clinical trials. Emergency Preservation and Resuscitation (EPR) will be used to induce rapid profound hypothermia, a state in which no oxygen delivery is required for 3+ hours, buying life-saving time for transport to a hospital followed by immediate surgical repairs and medical interventions. EPR is the next revolutionary resuscitation step in saving the lives of loved ones too precious to be lost.

$65,536

raised
97
Investors
$65M
Valuation
$0.50
Price per Share
$200.00
Min. Investment
Preferred
Shares Offered
Equity
Offering Type
$1.07M
Offering Max
2
Days Left

$65,536

raised
97
Investors
$65M
Valuation
$0.50
Price per Share
$200.00
Min. Investment
Preferred
Shares Offered
Equity
Offering Type
$1.07M
Offering Max
2
Days Left

Rewards

Get rewarded for investing more into EPR-Technologies, Inc.:

$200+
Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
$1,000+
Investment
$1,000+
Receive 10% bonus shares
$5,000+
Investment
$5,000+
Receive 20% bonus shares
$10,000+
Investment
$10,000+
Receive 40% bonus shares

Reasons to Invest

  • Our technology introduces a new standard of emergency care by offering one more chance at survival via EPR induction, if and when CPR fails. 

  • According to our industry research, the EPR clinical trial is currently the only FDA-approved clinical trial for rapid profound hypothermia following the success of large animal EPR experiments.

  • The Emergency Medicine industry’s use of therapeutic hypothermia and temperature management has grown in recent years, but our company appears to be the first and only company poised to deliver rapid profound hypothermia as a viable treatment option when CPR fails.





Overview


A Life-Saving New Approach to Resuscitation



EPR provides an opportunity to save the life of a loved one when CPR procedures fail by inducing rapid profound hypothermia. Our proprietary techniques and products are planned to be used in serious trauma cases such as auto accidents and shootings, sudden cardiac arrest, and other medical emergencies. 


EPR’s goal is to provide an emergency preservation period for 3+ hours to buy critical time for transport and medical/surgical interventions and repairs, followed by delayed resuscitation. EPR provides a period of tolerance to ischemia (that is, a lack of, or need for, oxygen), thereby preventing cell death even when there is no heartbeat, no breathing, and no brain function. 


By inducing a state in which no oxygen delivery is required for 3+ hours, EPR buys time for transport to a hospital followed by immediate surgical repairs and medical interventions. After essential surgical repairs, the patient is rewarmed and resuscitated. 

 


EPR-Technologies, Emergency Preservation and Resuscitation (EPR), rapid profound hypothermia, and the ongoing clinical trial at Maryland Shock Trauma are well known in the medical trauma community. The lead trauma surgeon for the clinical trial, Dr. Samuel Tisherman, M.D., at Maryland Shock Trauma recently gave a “TEDx” talk about EPR. 



Our company’s products are in final prototyping stages, and we await completion of the EPR clinical trial to put FDA-approved EPR products and training materials on the market. 


EPR-Technologies is dedicated to the memory and vision of Dr. Peter Safar, “the father of cardiopulmonary resuscitation” (Source), for pioneering the idea of rapid profound hypothermia to advance emergency medical resuscitation capabilities in order “to save hearts and brains too good to die”. 

THE PROBLEM


Too Many Lives Are Lost Annually Due to Failed CPR Attempts


The numbers for CPR success remain limited, at 12% for out-of-hospital use and 24-40% in-hospital. (Source) For serious trauma leading to cardiac arrest, CPR only has a success rate of 5% at best. (Source)

CPR is of particularly limited value to those victims whose cardiac arrest is a result of exsanguination (massive loss of blood) or sudden cardiac arrest (SCA).  

This is because the required surgery for quickly controlling massive blood loss cannot be performed in the field or even in trauma centers without sufficient time, so the victims generally die before they are transported to the nearest medical facility or before they receive definitive life-saving care. 



Similarly, the underlying causes leading to sudden cardiac arrest may not be easily reversed by CPR and defibrillation. Time is needed for a definitive intervention. Currently, if CPR doesn’t work immediately, there is no alternative besides death. Our goal is to change that and provide another option for survival. 


THE SOLUTION


Providing an Opportunity to Survive Failed CPR


EPR provides the technology for immediate and targeted intervention that can isolate the heart, brain, and other vital organs to impose a state of clinical preservation, providing time for transport of the patient to a trauma center with specialized acute care and advanced medical/surgical intervention capabilities. 


We believe EPR is a revolutionary opportunity for survival for victims who are currently unrecoverable following:

  1. Trauma and exsanguination cardiac arrest
  2. SCA unresponsive to defibrillation
  3. Massive stroke
  4. Other medical conditions that require medical/surgical interventions


How EPR Saves Lives


The procedure for inducing emergency preservation for up to 3+ hours requires cooling the patient within about 7 minutes of cardiopulmonary arrest or cessation of CPR. 


This rapid profound hyperthermia cooling is achieved by flushing the patient’s vasculature with a cold-flush solution at a temperature of approximately 1°C to 2°C (33.8°F to 35.6°F). The cold-flush solution is typically introduced into the patient through the patient’s arteries, such as the aorta. The patient is then cooled to a tympanic membrane temperature of about 7°C-10°C (44.6°F to 50°F) in less than 10-12 minutes. 



The patient is then transported so they can receive acute care at a hospital, including surgical repairs and medical interventions that they would not have had the opportunity to receive without EPR. 



The patient is ultimately resuscitated by the re-introduction of blood bank donor blood, using cardiopulmonary bypass (CPB), followed by re-warming. The patient ideally is re-warmed and resuscitated within 3+ hours or less from the time of initiation of emergency preservation and rapid profound hypothermia. 


The company plans to follow a business model somewhat similar to the introduction of Automatic External Defibrillators (AEDs) decades ago, when AEDs added one more chance to get the heart started when chest compressions and mouth-to-mouth breathing were inadequate. The use of AEDs quickly became the emergency standard of care, and we hope to replicate that success. 


What makes EPR unique is the extended, 3+hour period of emergency preservation for transport to a hospital for surgical repairs followed by delayed resuscitation. 


For the first time, resuscitation doesn’t require immediate success.


THE MARKET


Pioneering an Industry to Meet Market Needs


g

Approximately 2,000 people per day die from traumatic exsanguination, cardiac arrest or sudden cardiac arrest despite receiving CPR. That’s approximately 83 victims per hour: one victim of non-traumatic cardiac arrest every minute and one victim of trauma every three-to-four minutes. (SourceSource)


According to our industry research, we believe we are the leaders in bringing EPR to market, opening up a new standard of care that hasn't previously been available. The primary markets we plan to target include Level I Trauma Hospitals, Level II through Level V Hospitals, Emergency Rooms, ICUs, Patient Floors, Ambulances, and military combat casualty care needs. 


Emergency Medicine is already demonstrating trends towards investing in cooling equipment related to mild hypothermia treatments. Therapeutic Hypothermia and Temperature Management markets are increasing each year as these exciting new technologies are adopted. 


Meanwhile, the Automated External Defibrillator (AED) market is also rapidly expanding. We believe both of these trends demonstrate interest in EPR technology because it is a similar investment in life-saving equipment, disposables, and training for when CPR fails. 

OUR TRACTION


Successful Trials, R&D Support, and Proprietary Technology

g

For the past ten+ years, the Safar Center for Resuscitation Research at the University of Pittsburgh has successfully pursued large animal studies in which the use of rapid aortic cold flush to induce emergency preservation (EP) was followed by delayed resuscitation and full recoveries of the animals. 


These revolutionary studies have formed the basis of the emergency preservation and resuscitation (EPR) technology for our planned, patented product line of disposable EPR-Kits, EPR Cold Flush Solutions with additives, and EPR equipment for both emergency in-hospital and field use. 


An FDA-approved clinical trial is currently underway at Maryland Shock Trauma at the University of Maryland, Baltimore, MD. Maryland Shock Trauma is a nationally recognized Level I trauma center pioneering designs, facilities, and capabilities for rapid trauma care with a strong interest in advanced resuscitation techniques like EPR. 


The U.S. Army Medical Research and Development Command has always been a very strong supporter of innovative resuscitation techniques to save combat casualties suffering massive hemorrhagic and cardiac arrest on the battlefield. The Army was the first to realize the importance of EPR and supplied early R&D funding as well as current support for the EPR clinical trial. 


EPR-Technologies has several key patents-in-preparation which will be completed and submitted in the US. and foreign countries using money from this raise. 


The initial six patents-in preparation include: 

  1. Specific EPR Induction Kit

  2. Novel Aortic Access Catheter

  3. Specifically Configured Hospital Refrigerator-Pump

  4. Unique Guided Transthoracic Catheter

  5. Ambulance Portable Refrigerator-Pump System

  6. Oxygen Carrying Additive for EPR Induction Vascular Patency

WHY INVEST


Creating a New Emergency Medicine Standard of Care



Ultimately, our goal is for EPR to become the next emergency life-saving “Standard of Care'' procedure following failure of CPR on any victim. 


In the future, we see this leading to a successful revenue stream, growing each year, with 2nd and 3rd generation products enabling EPR-Technologies to remain a research and revenue leader in the sub-niche of emergency preservation and delayed resuscitation. 


Besides the most important goal of saving lives, being first in the medical emergency marketplace with a new innovative technique and products is an excellent opportunity for any startup company to dominate the branding and market space for revenue success and future strong potential as a business. 


With promising technology, patents soon to be filed, and a clinical trial underway, we are well on our way to achieving this vision. 


Join us as we create a revolutionary new approach to resuscitation and save lives everywhere. 





Offering Summary


Company

:

EPR-Technologies, Inc.

Corporate Address

:

23041 Wild Hunt Drive, Gaithersburg, MD 20882

Offering Minimum

:

$10,000.00

Offering Maximum

:

$1,070,000.00

Minimum Investment Amount

(per investor)

:

$200.00











Terms


Offering Type

:

Equity

Security Name

:

Preferred Stock

Minimum Number of Shares Offered

:

20,000

Maximum Number of Shares Offered

:

2,140,000

Price per Share

:

$0.50

Pre-Money Valuation

:

$65,000,000.00











*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.

Investment Incentives and Bonuses*

Time-Based: 

Friends and Family Early Birds

Invest in the first 7 days and receive an additional 25% bonus shares.

Super Early Birds

Invest in the next 7 days and receive an additional 20% bonus shares.

Early Birds

Invest in the next 7 days and receive an additional 15% bonus shares.


Amount-Based:

$1,000+ 

Receive 10% bonus shares

$5,000+ 

Receive 20% bonus shares

$10,000+ 

Receive 40% bonus shares

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

EPR-Technologies, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Preferred Stock at $0.50 / share, you will receive 110 shares of Preferred Stock, meaning you'll own 110 shares for $50. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Insider Investment Notice

Officers, directors, executives, and existing owners with a controlling stake in the company (or their immediate family members) may make investments in this offering. Any such investments will be included in the raised amount reflected on the campaign page.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Salary payments made to one’s self, a friend or relative. Vendor payments.

Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$24.00 USD
$39.00 USD
Cash And Cash Equivalents
$24.00 USD
$39.00 USD
Accounts Receivable
$0.00 USD
$0.00 USD
Short Term Debt
$0.00 USD
$0.00 USD
Long Term Debt
$0.00 USD
$0.00 USD
Revenues And Sales
$0.00 USD
$0.00 USD
Costs Of Goods Sold
$0.00 USD
$0.00 USD
Taxes Paid
$0.00 USD
$0.00 USD
Net Income
$0.00 USD
$0.00 USD

Risks

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Updates

DotCom Magazine Names EPR-Technologies the 2022 Impact Company of the Year

18 days ago

DotCom Magazine has revealed its annual list of America’s most impactful privately held companies, and EPR-Technologies, Inc., has been designated the 2022 Impact Company of the Year (EPR-Technologies: DotCom Magazine Reveals Its Annual List of America’s Most Impactful Privately Held Companies - EPR-Technologies Awarded 2022 Impact Company of The Year Award - DotCom Magazine-Influencers And Entrepreneurs Making News or https://www.dotcommagazine.com/2022/05/epr-technologies-dotcom-magazine-reveals-its-annual-list-of-americas-most-impactful-privately-held-companies-epr-technologies-awarded-2022-impact-company-of-the-year-award/#:~:text=The%20DotCom%20Magazine%20Impact%20Company%20of%20The%20Year,a%20positive%20difference%20in%20an%20incredibly%20unique%20year). It’s great that our StartEngine campaign has brought EPR-Technologies to the attention of DotCom Magazine as well as several high-value investors and organizations, providing the company the opportunity to continue pursuing significant funding even after our StartEngine campaign ends. Don’t miss the chance to join our StartEngine investment campaign to support our advanced emergency medical resuscitation efforts. EPR-Technologies remains ceaselessly focused on success to save the lives of loved ones. Thank you for investing!  - Lyn Yaffe, EPR-Technologies, Inc.

EPR CAMPAIGN CLOSING SOON

25 days ago

EPR-Technologies’ StartEngine crowdfunding campaign will be closing soon. A very sincere “thank you” to our visionary investors to date. In the opinion of EPR-Technologies, rapid profound hypothermia procedures will be the future standard of care when cardiopulmonary resuscitation (CPR) fails. Medical advances are always focused on preventing illness, suffering, and premature death, and EPR-Technologies is dedicated to providing one more chance at survival when standard CPR fails. Our StartEngine campaign has brought EPR-Technologies to the attention of several high-value investors and organizations, so the company has the opportunity to continue pursuing significant funding even after our StartEngine campaign ends. Don’t miss this StartEngine early investment chance to join our advanced emergency medical resuscitation efforts. EPR-Technologies will remain ceaselessly focused on success to save the lives of loved ones. Thank you for investing!  - Lyn Yaffe, EPR-Technologies, Inc.

DOTCOM MAGAZINE EPR PODCAST AVAILABLE

27 days ago

The “DotCom Magazine” EPR podcast I recently did with the host Andy Jacob to discuss EPR-Technologies and rapid profound hypothermia, is now available at https://www.dotcommagazine.com/2022/05/dr-lyn-yaffe-chairman-ceo-epr-technologies-inc-a-dotcom-magazine-interview/ or at YouTube https://youtu.be/U_dyduTQzsU. The YouTube URL is shown above just in case the embedded video does not play on your browser. Many thanks to our investors, very much appreciated!!! Lyn Yaffe, EPR-Technologies, Inc.





Notice of Material Change in Offering

about 1 month ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the EPR-Technologies, Inc. offering. Here's an excerpt describing the specifics of the change:


Issuer is extending the length of their campaign by 30 days.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

“FROM LAB TO LAUNCH” BY QUALIO EPR PODCAST AVAILABLE

about 2 months ago

The “From Lab to Launch” by Qualio EPR podcast I recently did with the host Kelly Stanton to discuss EPR-Technologies and rapid profound hypothermia, is now available on YouTube (https://www.youtube.com/watch?v=aEbz6_7W8g8). The YouTube URL is shown above just in case the embedded video does not play on your browser. Many thanks to our early investors, very much appreciated!!! Lyn Yaffe, EPR-Technologies, Inc.




THE “CHRIS VOSS SHOW” EPR PODCAST AVAILABLE

2 months ago

The “Chris Voss Show” EPR podcast, I did recently with the host Chris Voss, to discuss EPR-Technologies and rapid profound hypothermia, is now available on YouTube (https://youtu.be/w_qoLKBwreU) and the “Chris Voss Show” website (https://thechrisvossshow.com/the-chris-voss-show-podcast-dr-lyn-yaffe-chairman-and-ceo-chairman-of-epr-technologies-inc/). The YouTube URL is shown above just in case the embedded video does not play on your browser. Many thanks to our early investors, very much appreciated!!! Lyn Yaffe, EPR-Technologies, Inc.



MY “DAY IN DAY OUT” EPR PODCAST AVAILABLE

3 months ago

The “Day In Day Out” EPR podcast I did this past Tuesday, April 5, 2022, hosted by Muyiwa Adebiyi, on his Apple Podcast to discuss EPR-Technologies and rapid profound hypothermia, is now available on YouTube (https://www.youtube.com/watch?v=5PTtRdDaK1c) and the “Day In Day Out” site (https://bit.ly/3uk6Jdq). The YouTube URL is shown above just in case the embedded video does not play on your browser. Many thanks to our early investors, very much appreciated!!! Lyn Yaffe, EPR-Technologies, Inc.




MORE HISTORY – PETER SAFAR AND RESUSCI-ANNIE

3 months ago

Many thanks to our early investors!!! Resusci-Annie, also known as Rescue Anne, Resusci-Anne, CPR Annie, Resuscitation Annie, Little Annie, or CPR Doll is a medical simulator used for teaching cardiopulmonary resuscitation (CPR) to both emergency workers and the general public. Resusci-Annie was developed by the Norwegian toy maker Åsmund S. Lærdal and Dr. Peter Safar, who as mentioned before, is considered the “father of cardiopulmonary resuscitation” and the original driving force behind Emergency Preservation and Resuscitation (EPR). Resusci-Annie is manufactured by the Norwegian company Laerdal Medical. The interesting history of Resusci-Annie may be seen at the YouTube URL (https://youtu.be/dfvvrO_Mbbc) just in case the embedded video does not play on your browser. Thanks, Lyn Yaffe, EPR-Technologies, Inc.



EPR CLINICAL TRIAL OVERVIEW OF PROCEDURES – PART #2

3 months ago

Many thanks to our early investors!!! EPR Resuscitation Protocol – Patients are enrolled in the EPR feasibility clinical trial after emergency trauma center thoracotomy (surgical incision into the chest wall) and at least 5 minutes open-chest resuscitation attempts fail to achieve return of spontaneous circulation (ROSC). Preparation for aortic flush with ice-cold saline begins with a purse string suture placed into the descending thoracic aorta, followed by a transverse aortotomy (incision into the aorta). Then, an aortic cannula is inserted directly into the aortotomy site, and the right atrial appendage is amputated for venous drainage. Aortic flush then is initiated with ice-cold saline using a roller pump at a speed of 2-3 liters/minute. The goal is to cool the brain and other vital organs to 5⁰C-15⁰C (41⁰F-59⁰F) as rapidly as possible. Once the target profound hyperthermic temperature is reached, the patient is quickly transported to the operating room (OR) for critical surgical repairs utilizing a damage control surgical approach. This damage control approach may include extension of the left thoracotomy to the right side, laparotomy, or peripheral vascular procedures to achieve hemostasis. Simultaneously, additional cannulas may be placed in the femoral vessels via cutdown or percutaneous techniques to enable implementation of cardiopulmonary bypass (CPB) for delayed resuscitation after surgical repairs. Direct cannulation of the heart or great vessels may also be performed, as necessary. After hemostasis from major vascular injuries has been achieved, reperfusion and rewarming via CPB begins. Unless the aortic flush cannula is used for ongoing CPB support, this cannula is removed and the aortotomy closed. Blood, plasma, and platelet transfusions are administered as needed. The resuscitation goal is slow rewarming, keeping the CPB water bath temperature about 5⁰C-10⁰C (41⁰F-50⁰F) above ear tympanic membrane temperature. During this rewarming, any bleeding is managed surgically and with correction of any coagulopathy. Weaning from CPB may begin once the patient has been rewarmed to approximately 34⁰C (93.2⁰F) with spontaneous restoration of cardiac function or following defibrillation as may be necessary. Patients are then transported to the intensive care unit (ICU). Mild hypothermia (34⁰C-35⁰C or 93.2⁰F-95⁰F) is continued for 12-24 hours to decrease the risk of any neurologic dysfunction. Post-resuscitation care subsequently follows standard medical/surgical practices. Thanks, Lyn Yaffe, EPR-Technologies, Inc.

UPCOMING “DAY IN DAY OUT” PODCAST APPEARANCE ON APRIL 5, 2022, AT 2:00 PM EDT

3 months ago

I will be interviewed on Tuesday, April 5, 2022, at 2:00 PM, by Muyiwa Adebiyi, on his Apple Podcast called “Day In Day Out” (https://podcastaddict.com/podcast/day-in-day-out/3309764) to discuss EPR-Technologies and rapid profound hypothermia. The podcast will be recorded by Zoom, and the video of the episode will be uploaded to YouTube and the audio will be uploaded to various podcasting sites. After the interview, I’ll obtain the YouTube and Apple Podcast information and post the URLs via a future update. And again, many thanks to our early investors, very much appreciated!!! Lyn Yaffe, EPR-Technologies, Inc.

MORE HISTORY – PETER SAFAR AND THE EARLY DAYS OF RESPIRATORY RESUSCITATION

3 months ago

Many thanks to our early investors, very much appreciated!!! Here’s some more history about Dr. Peter Safar, M.D. (1924-2003), considered the “father of cardiopulmonary resuscitation” (CPR), and the original driving force behind Emergency Preservation and Resuscitation (EPR). In the very early days during the development of mouth-to-mouth resuscitation, supported by the US Army, much like EPR research has been supported by the US Army, a video was produced comparing the different techniques at the time for respiratory resuscitation. The conclusive result of the research was that the mouth-to-mouth resuscitation technique developed by Peter Safar was the best approach. The video shows a young Peter Safar discussing the various respiratory resuscitation techniques studied at that time. Dr. Safar’s discussion may be seen at the YouTube URL (https://youtu.be/FG2qy4CQy0Q) just in case the embedded video below does not play on your browser. Please excuse the somewhat high-pitched audio which was typical of many audio recordings in those years. The video shows CPR history-making research events from decades ago!!! Thanks, Lyn Yaffe, EPR-Technologies, Inc.



WIRED MAGAZINE, UK, CITED EPR AS 1 OF 19 THINGS THAT MADE THE WORLD A BETTER PLACE IN 2019!!!

3 months ago

Many thanks to our early investors, very much appreciated!!! Back in 2019 WIRED Magazine in the UK cited “19 things that made the world a better place”. Emergency Preservation and Resuscitation (EPR) made the list. Below is an image of the EPR portion of the article or go to the URL https://www.wired.co.uk/article/2019-positive-news and scroll down the article to find “Humans placed in suspended animation.” In the article, the use of the term “A&E” means Accident and Emergency, it’s the UK equivalence of Emergency Room in the US. EPR continues to strive to “make the world a better place.”  Thanks, Lyn Yaffe, EPR-Technologies, Inc.

MY EPR VIDEO OVERVIEW POSTED!!!

3 months ago

Many thanks to our early investors, very much appreciated!!! My EPR video overview describing the efforts and significance of a successful EPR-Technologies endeavor has been placed at the top of the EPR StartEngine Campaign Page. If you have not visited our StartEngine Campaign Page recently, please take a look at my video and provide any comments or questions, I will reply with 24 hours at most. Thanks, Lyn Yaffe, EPR-Technologies, Inc.

MORE HISTORY – PETER SAFAR AND THE FREEDOM HOUSE AMBULANCE SERVICE

3 months ago

Many thanks to our early investors!!! Freedom House Ambulance Service was a pioneering social and emergency medical project that trained unemployed Black citizens in Pittsburgh during the late 1960s and early 1970s to provide what was then state-of-the-art prehospital emergency medical care. The Freedom House leaders were Dr. Peter Safar (1924-2003), the “father of cardiopulmonary resuscitation (CPR)” and pioneering force behind Emergency Preservation and Resuscitation (EPR), and his protégé, Dr. Nancy Caroline. The success of Freedom House demonstrated national standards for paramedic training and equipment. However, the Freedom House program ended abruptly in 1975 when Pittsburgh's city administration at the time cited economic constraints for continued support of Freedom House. However, African Americans and white citizens, as well as local newspapers, instead understood the city's diminishing support of the program in racial terms. Nevertheless, Freedom House was the forerunner of modern paramedic services and is a model for EPR point-of-injury care in the future with successful funding support. The story of Freedom House and Dr. Safar’s role may be seen at the YouTube URL (https://youtu.be/SvOHFMQRgAY) just in case the embedded video does not play on your browser, and a published journal reference is: J Hist Med Allied Sci, 2019 Oct 1;74(4):440-466. doi: 10.1093/jhmas/jrz041, at https://pubmed.ncbi.nlm.nih.gov/31592527/. Thanks, Lyn Yaffe, EPR-Technologies, Inc.


WATCH MY PODCAST APPEARANCE TOMORROW, 23 MAR 2022, AT 4:00 PM EDT

3 months ago

I will be interviewed tomorrow, 23 March 2022, at 4:00 PM EDT, for about 10 minutes, to briefly discuss EPR-Technologies and rapid profound hypothermia on the podcast radio station www.chatandspinradio.com, so if you’re available, please tune in!!! And many thanks to our early investors, very much appreciated!!! Lyn Yaffe, EPR-Technologies, Inc.

EPR CLINICAL TRIAL OVERVIEW OF PROCEDURES – PART #1

3 months ago

Many thanks to our early investors!!! EPR Clinical Trial Design - The Emergency Preservation and Resuscitation (EPR) clinical trial is designed to test the feasibility and safety of inducing rapid profound hypothermia to enable delayed resuscitation in trauma victims who have suffered cardiac arrest. Cardiac arrest trauma victims are only enrolled in the EPR feasibility clinical trial when the subjects meet the inclusion criteria and medical/surgical personnel trained in EPR procedures are available. Trauma victims may be enrolled in the EPR clinical trial if they meet all of the following criteria: (1) At least 18 years of age; (2) Trauma is a penetrating injury; (3) At least one sign of life including pulse, respirations, reactive pupils, or spontaneous movement is present within the initial 5 minutes of arrival at the trauma center, but disappear necessitating initiation of cardiopulmonary resuscitation attempts; (4) No pulses are present in large arteries, including the carotid and femoral arteries; and (5) Trauma victims remain pulseless after emergency thoracotomy and at least 5 minutes of open-chest resuscitation attempts. Trauma victims are excluded from the EPR clinical trial if (1) Significant head trauma is visible or suspected; (2) Trauma victim’s cardiac rhythm demonstrates electrical asystole; and (3) External assessment of the injuries suggests massive tissue trauma or blunt trauma involving multiple body regions. EPR Clinical Trial Specific Aims – (1) To test the use of rapid profound hypothermia in circulatory cardiac on patients who have no chance of survival with current therapies; (2) To test EPR by rapidly inducing profound hypothermia through the infusion of ice-cold saline via a large-bore catheter placed into the proximal, descending aorta to attain a tympanic membrane temperature between 5⁰C-15⁰C maximum (41⁰F-59⁰F), and following surgical repairs/hemostasis, delayed resuscitation may be accomplished with cardiopulmonary bypass (CPB); and (3) To examine the safety and efficacy of EPR rapid profound hypothermia and delayed resuscitation, with the development of multiple organ system dysfunction, neurologic function, and survival being used as secondary endpoints. Thanks, Lyn Yaffe, EPR-Technologies, Inc.

SOCIAL MEDIA WILL BE GETTING THE EPR WORD OUT!!!

3 months ago

Many thanks to our early investors, very much appreciated!!! EPR-Technologies is very happy to announce that William “Tedd” Howsare is now managing our out-reach via social media, including Facebook, Instagram, and LinkedIn, as well as updating the EPR website, press releases, and other marketing endeavors to get information about our EPR StartEngine Campaign raise widely disseminated. Tedd is very experienced with crowdfunding raises, and related marketing and investment strategies to achieve a successful raise. I will periodically post updates about Tedd’s ongoing efforts on behalf of EPR-Technologies. Thanks, Lyn Yaffe, EPR-Technologies, Inc.

A LITTLE MORE HISTORY – SAFAR AND MOUTH-TO-MOUTH RESUSCITATION

3 months ago

A big “thank you” to all our early investors!!! Some more history about Dr. Peter Safar, M.D. (1924-2003), considered the “father of cardiopulmonary resuscitation” (CPR), and the original driving force behind Emergency Preservation and Resuscitation (EPR). Dr. Safar established mouth-to-mouth breathing as an integral procedure with chest compressions for successful cardiopulmonary resuscitation (CPR). Attached is an historic video of Dr. Safar performing early experiments of mouth-to-mouth breathing on a research laboratory associate whose respiratory muscles were paralyzed with a drug for the demonstration, “boldly going where no one had gone before”. The mouth-to-mouth breathing, being performed by Dr. Safar, may be seen at the YouTube URL (https://youtu.be/3PVFOMPCOz4) just in case the embedded video does not play on your browser. Thanks, Lyn Yaffe, EPR-Technologies, Inc.


CASES OF ACCIDENTAL PROFOUND HYPOTHERMIA DEMONSTRATE ITS FEASIBILITY AND SUCCESS

3 months ago

Thanks to all our early investors!!! Three adults, 2 buried in avalanches and 1 submerged in ice-cold water in a glacier crevasse, suffered accidental profound hypothermia and total cardiorespiratory arrest, lasting 2-1/2 to 4 hours prior to resuscitation. The patients fully recovered their mental and physical abilities following re-warming and delayed resuscitation. While these anecdotal profound hypothermia cases occurred in otherwise healthy adults, the cases demonstrate that prolonged profound hypothermia, in and of itself, does not preclude delayed resuscitation success and full recovery. The goal of EPR-Technologies is to demonstrate that the same successful results may be achieved in cardiopulmonary arrest victims of severe trauma, sudden cardiac arrest, and other causes of currently unresuscitable cardiac arrest.  Read the published science article about these 3 cited cases at: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC1352533/Thanks, Lyn Yaffe, EPR-Technologies, Inc.

DON’T CONFUSE EPR’S PROFOUND HYPOTHERMIA WITH MILD HYPOTHERMIA!!!

4 months ago

A very sincere “thank you” to all our early investors!!! If you have any questions or comments, please post them in the “Comments” section near the bottom of the EPR-Technologies’ Campaign Page, and I will reply within 24 hours. Also, as mentioned on the EPR Campaign Page, it is very important not to confuse the use of mild hypothermia with EPR’s profound hypothermia. Mild and profound hypothermia have very different medical indications for use, different techniques, and very different treatment goals. And EPR’s profound hypothermia is a new, unique, revolutionary emergency intervention. Just to make this point as clear as possible, below is a summary of distinguishing features for mild versus profound hypothermia.

MILD HYPOTHERMIA FEATURES: (1) Currently used for severe heart attack and cardiac arrest following successful CPR, but the patient remains unconscious; (2) Mild hypothermia cooling to 33⁰C-36⁰C (91.4⁰F-96.8⁰F) is the optimal treatment to prevent brain damage or other complications from inadequate oxygen supply during and immediately after the cardiac arrest and CPR; (3) Mild cooling should be initiated within 2-4 hours after successful CPR; (4) Cooling time to target temperature should be achieved in approximately 1 hour; (5) Mild hypothermia may be achieved with 1-liter cold saline intravenous (IV) infusion, followed by surface cooling body wraps, cooling pads, endovascular cold probe, or ice packs; (6) During mild hypothermia, the heart continues to beat, breathing continues, and brain waves remain present; (7) Patient is kept sedated to prevent shivering; (8) Mild hypothermia is maintained for 24-36 hours, then the patient is slowly rewarmed; and (9) Potential benefits for mild hypothermia are also being studied in traumatic brain injury, neuroprotection, and stroke.

PROFOUND HYPOTHERMIA FEATURES: (1) EPR’s profound hypothermia is to be used following failed CPR in severe trauma + exsanguination cardiac arrest, sudden cardiac arrest, and heart attack + ventricular fibrillation (VF) unresponsive to defibrillation; (2) EPR may also be used in cardiac surgical emergencies, toxin, venom, poison and chemical/biological warfare agent exposures, opioid overdoses, drowning, and respiratory insufficiencies that lead to unresuscitable cardiac arrest; (3) EPR is designed to save currently unrecoverable lives when CPR fails; (4) Profound cooling is in the range of 5⁰C-15⁰C (41⁰F-59⁰F); (5) Cooling time to target temperature must be very rapid to prevent vital organ damage; (6) Profound hypothermia is achieved within in 7-12 minutes using 20-40 liters of ice-cold saline (potentially plus additives) rapidly infused into a major artery or the proximal descending aorta followed by surgical & medical interventions; (7) The 20-40 liters of ice-cold saline is infused at a minimum of 4-liters per minute; (8) With profound cooling, no heartbeat, no breathing, and no brain waves are present, and no oxygen delivery is necessary for cellular viability to continue at profound hypothermic temperatures; (9) EPR buys critical time up to 3 hours for necessary surgical and medical treatments prior to placing the patient on cardiopulmonary bypass (CPB) for rewarming; (10) The EPR clinical trial is currently underway at Maryland Shock Trauma in Baltimore; and (11) EPR’s profound hypothermia is a new, unique, revolutionary, emergency medical intervention. Thanks, Lyn Yaffe, EPR-Technologies, Inc.

The Term Suspended Animation

4 months ago

A hearty thanks to our early investors!! Help spread the EPR word to family and friends!! Suspended animation is much more familiar in science fiction than in medicine, but EPR researchers did use the term suspended animation to describe the impact of rapid profound hypothermia in early experiments. Like the current, preferable term “Emergency Preservation and Resuscitation” (EPR), suspended animation may be defined as treatment to preserve the viability of the entire organism during ischemia or lack of oxygen, such as during cardiac arrest or severe shock. The goal of both the early experiments in suspended animation, and now true for EPR, was to induce rapid profound hypothermia. If immediate preservation sustains viability of the brain and body, then there is critical time for transport and surgical repairs to be followed by restoration of blood volume and resuscitation, using cardiopulmonary bypass (CPB). The attached video has a little fun with the term suspended animation, then discusses the serious efforts in Emergency Preservation and Resuscitation. The YouTube URL (https://youtu.be/7LWXeEUDhY4) is provided just in case the embedded video does not play on your browser. Thanks, – Lyn Yaffe, EPR-Technologies, Inc.

A Little EPR History

4 months ago

Hello!! Many thanks to our early investors, very much appreciated. Now, together, we are dedicated to saving lives!! I wanted to begin these updates with some history about Dr. Peter Safar, M.D. (1924-2003), considered the “father of cardiopulmonary resuscitation” (CPR), and the original driving force behind Emergency Preservation and Resuscitation (EPR). Dr. Safar was interviewed by ABC News years ago, saying a few words about cooling and forecasting the research success that was to become EPR. Attached is that ABC News interview and its YouTube URL (https://youtu.be/c4u79mx49ns) just in case the embedded video does not play on your browser. Thanks, – Lyn Yaffe, EPR-Technologies, Inc.

Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

{{profileCtrl.newComment.body.length}}/2500
Please sign in to post a comment.
Please use Updates for communications.
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}